Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neuro- sensory abnormalities play etiological roles. (DEWS II Report, 2017).~For the treatment and prevention of dry eye disease (DED) there are a number of treatment modalities available, depending on the severity and classification (aqueous deficient / evaporative) of the disease. The liposomal eye spray Tears Again® (TA, Optima Medical Swiss AG - medical device with CE marking) represents an option to treat mild to moderate evaporative DED. A novel preservative-free eye spray, Ectoin® Eye Spray - Colloidal (EES09; bitop AG -medical device with CE marking), was developed, in which colloids (colloidal lecithin emulsion) serve as a carrier for Ectoin. Ectoin is known as a natural cell-protective and inflammatory-inhibiting molecule. The principle mode of action of Ectoin is based on the physical interaction of this compatible solute with water and the resulting effects of the Ectoin-Hydro-Complex on the tissue treated.~The aim of this study is to subjectively and objectively evaluate the efficacy and tolerability of preservative-free Ectoin® Eye Spray - Colloidal and to compare the efficacy and tolerability between Ectoin® Eye Spray - Colloidal and Tears Again® in patients with mild-moderate dry eye disease.
Subjective and objective evaluation of the efficacy and tolerability of preservative-free Ectoin® Eye Spray - Colloidal and comparison of the efficacy and tolerability between Ectoin® Eye Spray - Colloidal and Tears Again® in patients with mild-moderate dry eye disease